| |
Centre for Policy on Ageing | |
 | |
|
Bevacizumab for neovascular age related macular degeneration (ABC Trial)
— multicentre randomised double masked study | | Author(s) | Adnan Tufail, Praveen J Patel, Catherine Egan |
| Journal title | British Medical Journal, vol 340, no 7761, 26 June 2010 |
| Pages | p 1398 |
| Source | www.bmj.com BMJ2010;340:c2459 |
| Keywords | Visual impairment ; Preventative medicine ; Drugs ; Clinical surveys. |
| Annotation | Are intravitreous bevacizumab injections better than standard care at improving vision in patients with neovascular age related macular degeneration (AMD)? This summary of a paper published on bmj.com reports on 131 patients age 50+ (mean age 81) randomised to two intervention groups: 65 eyes of 65 patients to bevacizumab 1.25mg intravitreously and 66 eyes of 66 patients to standard care (pregaptanib sodium, venterporfin, or sham). This study provides the first level 1 evidence supporting use of intravitreous bevacizumab every 6 weeks, resulting in a reduction in hospital visits by a third over conventional monthly dosing while maintaining improvement in vision. (RH). |
| Accession Number | CPA-100630211 A |
| Classmark | BR: LK2: LLD: 3G * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|